ArticleBMC infectious diseases2025
Meningitis caused by Aspergillus fumigatus: a case report.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAspergillus fumigatus is a common pathogen that causes intracranial aspergillosis. A. fumigatus intracranial infection mainly occurs in the brain parenchyma. Head CT or MRI examination showed aspergillous abscess, which is extremely rare to caused meningitis alone. We report a case of aspergillosis meningitis with short-term death.
methodWe utilized the DNBSEQ™ sequencing platform, which employs DNA nanoballs (DNBs) technology. Briefly, DNBs are arrayed on a patterned flow cell, where DNA polymerase catalyzes the incorporation of fluorescently labeled nucleotides during sequencing-by-synthesis. The emitted fluorescence signals are digitally captured and computationally processed to generate high-accuracy base sequence data. CASE PRESENTATION: A 51-year-old woman with a medical history of post-hepatitis B cirrhosis, type 2 diabetes mellitus, and thyroid carcinoma presented with acute-onset altered mental status. Physical examination revealed positive meningeal signs. Initial neuroimaging studies, including two serial head CT scans and two MRI examinations, showed no evidence of fungal abscess formation in the brain parenchyma. The diagnosis of A. fumigatus meningitis was confirmed through cerebrospinal fluid (CSF) analysis, including metagenomic next-generation sequencing (mNGS) and galactomannan (GM) testing. Despite prompt initiation of voriconazole therapy, the patient’s condition deteriorated, resulting in death after 10 days of treatment.
conclusionA. fumigatus meningitis represents a rare but life-threatening infection characterized by diagnostic challenges and alarmingly high mortality rates. Stringent diagnostic vigilance is essential to avoid diagnostic errors in these cases. The PMseq-DR platform, a high-throughput metagenomic sequencing technology for cerebrospinal fluid (CSF) analysis, provides a valuable diagnostic tool for rapid pathogen identification. For patients presenting with meningitis of unknown etiology following conventional diagnostic workup (including microbial culture, galactomannan assay, and 1-3-β-D-glucan testing), comprehensive CSF pathogen analysis becomes critical. In such scenarios, prompt implementation of high-throughput sequencing is recommended to enable accurate diagnosis and timely therapeutic intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.